Preview

Современная ревматология

Расширенный поиск

Целекоксиб, эторикоксиб, мелоксикам и нимесулид: сравнение достоинств и недостатков

https://doi.org/10.14412/1996-7012-2011-662

Литература

1. <div><p>Ревматология. Клинические рекомендации. Под ред. акад. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2010; 752 с.</p><p>Амирджанова В.Н., Кайгородцева Е.Ю., Горячев Д.В. и др. Российский регистр Инфликсимаба. Влияние терапии на функциональное состояние больных ревматоидным артритом. Науч.-практич. ревматол. 2010; 6: 23-30.</p><p>Насонов Е.Л. Нестероидные противовоспалительные препараты (Перспективы применения в медицине). М.: Анко, 2000; 142 с.</p><p>Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА- ПРЕСС, 2009; 167 с.</p><p>Ziegler S., Huscher D., Karberg K. et al. Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997-2007: results from the National Database of the German Collaborative arthritis Centers. ARD 2010; 69: 1803-8.</p><p>Bingham C., Sebba A., Rubin B. et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 2007; 46(3): 496-507.</p><p>De Menezes S., Cury P. Efficacy of nimesulide versus meloxicam in the control of pain, swelling and trismus following extraction of impacted lower third molar. Int J Oral Maxillofac Surg 2010; 39(6): 580-4.</p><p>Bianchi M., Broggini M., Balzarini P. et al. Effects of nimesulide on pain and on synovial fluid concentrations of substance P, interleukin-6 and interleukin-8 in patients with knee osteoarthritis: comparison with celecoxib. Int J Clin Pract 2007; 61(8): 1270-7.</p><p>Moore R., Derry S., McQuay H. Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports. Arthr Res Ther 2008; 10(3): R53.</p><p>Shi W., Wang Y., Cheng N. et al. Metaanalysis on the effect and adverse reaction on patients with osteoarthritis and rheumatoid arthritis treated with non-steroidal antiinflammatory drugs. Zhonghua Liu Xing Bing Xue Za Zhi 2003; 24(11): 1044-8.</p><p>Silverstein F., Faich G., Goldstein J. et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxid long-term arthritis safety study. JAMA 2000; 84: 1247-55.</p><p>Hawkey C., Kahan A., Steinbrü K. et al. Gastrointestinal tolerability of meloxicam compared diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumat 1998; 37: 1142-7.</p><p>Singh G., Fort J., Goldstein J. et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med 2006; 119: 255-66.</p><p>Moore R., Derry S., Makinson G. et al. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systemic review and meta-analysis on information from company clinical reports. Arthr Res Ther 2005; 7: 644-65.</p><p>Simon L., Weaver A., Graham D. Antiinflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized control trial. JAMA 1999; 282; 1921-8.</p><p>Emery P., Zeidler H., Kvien T. et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet 1999; 354: 2106-11.</p><p>Singh G., Agrawal N., Makinson G. et al. Safety without borders: upper and lower gastrointestinal safety of celecoxib in a pooled analysis of 52 prospective, randomized, double-blinded, parallel-group clinical trials. EULAR-2010 THU0437.</p><p>Chan F., Lanas A., Scheiman J. et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173-9.</p><p>Goldstein J., Eisen G., Lewis B. et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 3.</p><p>Ramey D., Watson D., Yu C. et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin 2005; 21(5): 715-22.</p><p>Hunt R., Harper S., Watson D. et al. The gastrointestinal safety of the COX-2 selective inhibitor etori-coxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003; 98(8): 1725-33.</p><p>Cannon C., Curtis S., FitzGerald G. et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 18; 368(9549): 1771-81.</p><p>Laine L., Curtis S.P., Cryer B. et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2007; 369: 465-73.</p><p>Laine L., Curtis S., Langman M. et al. Lower gastrointestinal events in a doubleblind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology 2008; 135(5): 1517-25.</p><p>Dequerker J., Hawkey C., Kahan A. et al. Improvement in gastrointestinal tolerability of selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large Scale Evaluation of COX inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998; 37: 946-51.</p><p>Yocum D., Fleischmann R., Dalgin P. Safety and efficacy of meloxicam in the treatment of osteoarthritis. Arch Intern Med 2000; 160: 2947-54.</p><p>Furst D., Kolba K., Fleischmann R. Dose response and safety study of meloxicam up to 22.5 mg daily in rheumatoid arthritis: a 12 week multicenter, double blind, dose response study versus placebo and diclofenac. J Rheumatol 2002; 29: 436-46.</p><p>Singh G., Lanes S., Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic cpmplications with meloxicam. Am J Med 2004; 117: 100-6.</p><p>Lü cker P., Pawlowski C., Friedrich I. et al. Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee. Eur J Rheumatol Inflamm 1994; 14(2): 29-38.</p><p>Huskisson E., Macciocchi A., Rahlfs V. et al. Nimesulide versus diclofenac in the treatment of osteoarthritis of the hip or knee: an active controlled equivalence study. Curr Ther Res 1999; 60: 253-65.</p><p>Kriegel W., Korff K., Ehrlich J. et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int J Clin Pract 2001; 55(8): 510-4.</p><p>Bradbury F. How important is the role of the physician in the correct use of a drug? An observational cohort study in general practice. Int J Clin Pract (Suppl.)2004; 144: 27-32.</p><p>Минушкин О.Н. Использование препарата «Найз» у больных, страдающих сочетанной патологией суставов и поражением верхних отделов желудочно-кишечного тракта. Науч.-практич. ревматол. 2003; 5: 72-6.</p><p>Каратеев А.Е., Каратеев Д.Е., Лучихина Е.Л. и др. Эффективность и безопасность монотерапии высокими дозами НПВП при раннем артрите. РМЖ 2006; 16: 24-9.</p><p>Каратеев А., Каратеев Д., Насонов Е. Гастродуоденальная переносимость нимесулида (НИМЕСИЛ, Berlin Chemie) у больных с язвенным анамнезом: первое проспективное исследование безопасности селективных ЦОГ-2 ингибиторов у больных с высоким риском развития НПВП-индуцированных гастропатий. Науч.-практич. ревматол. 2003; 1: 45-8.</p><p>White W., West C., Borer J. et al. Risk of cardiovascular events in patients receiving celcoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 2007; 99(1): 91-8.</p><p>White W., Kent J., Taylor A. et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002; 39(4): 929-34.</p><p>Sowers J., White W., Pitt B. et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165(2): 161-8.</p><p>Curtis S., Ko A., Bolognese J. et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Сurr Med Res Opin 2006; 22(12): 2365-74.</p><p>Combe B., Swergold G., McLay J. et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford) 2009; 48(4): 425-32.</p><p>Trelle S., Reichenbach S., Wandel S. et al. Cardiovascular safety of non-steroidal anti- inflammatory drugs: network meta-analysis. BMJ 2011; 342: 7086 doi: 10.1136.</p><p>Chen Y., Jobanputra P., Barton P. et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008; 12(11): 1-278, iii.</p><p>Laporte J., Ibanez L., Vidal X. et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Safety 2004; 27: 411-20.</p><p>Gonzаlez E., Patrignani P., Tacconelli S. et al. Variability of risk of upper gastrointestinal bleeding among nonsteroidal anti-inflammatory drugs. Arthr Rheum 2010; 62(6): 1592-601.</p><p>MacDonald T., Morant S., Goldstein J. et al. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non- steroidal anti-inflammatory drugs. Gut 2003; 52(9): 1265-70.</p><p>Turajane T., Wongbunnak R., Patcharatrakul T. et al. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. J Med Assoc Thai 2009; 92(Suppl. 6): 19-26.</p><p>Fosbоl E., Folke F., Jacobsen S. et al. Cause-Specific Cardiovascular Risk Associated With Nonsteroidal Antiinflammatory Drugs Among Healthy Individuals. Circ Cardiovasc Qual Outcomes 2010; 3: 395-405.</p><p>Singh G., Mithal A., Triadafilopoulos G. Both selective COX-2 inhibitors and non- selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis; selectivity is with patients, not the drug. Ann Rheum Dis 2005; 64(Suppl. 3): 85.</p><p>McGettigan P., Henry D. Cardiovascular risk and inhibition of cyclooxygenase. JAMA 2006; 296: 1633-44.</p><p>Layton D., Hughes K., Harris S. et al. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatology (Oxford) 2003; 42(11): 1354-64.</p><p>Helin-Salmivaara A., Virtanen A., Veslainen R. et al. NSAID use and the risk of hospitalisation for first myocardial infarction in the general population: a national case-control study from Finland. Eur Heart 2006; 27: 1657-63.</p><p>Helin-Salmivaara A., Virtanen A., Veslainen R. et al. NSAID use and the risk of hospitalisation for first myocardial infarction in the general population: a national case- control study from Finland. Eur Heart 2006; 27: 1657-63.</p></div><br />


Для цитирования:


Каратеев А.Е., Karateyev A.E. Целекоксиб, эторикоксиб, мелоксикам и нимесулид: сравнение достоинств и недостатков. Современная ревматология. 2011;5(2):9-19. https://doi.org/10.14412/1996-7012-2011-662

For citation:


Karateev A.E., Karateyev A.E. Celecoxib, etoricoxib, meloxicam, and nimesulide: comparison of their merits and demerits. Modern Rheumatology Journal. 2011;5(2):9-19. (In Russ.) https://doi.org/10.14412/1996-7012-2011-662

Просмотров: 2309


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)